Physician profile
John D Clark
NPI 1235166943
$93,549.07
in general payments reported to CMS, 2019-2025
17 companies · $508 in 2025
The $508 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51K · 2020: $15K · 2021: $11K · 2022: $12K · 2023: $4,284 · 2024: $365 · 2025: $508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,571 · Food and Beverage: $1,247 · Travel and Lodging: $240 · Education: $99.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,570.50 |
| Food and Beverage | $1,247.13 |
| Travel and Lodging | $239.86 |
| Education | $99.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $43,435.22 | 2019-2025 | Mavenclad |
| Teva Pharmaceuticals USA, INC. | $17,105.66 | 2019-2024 | Austedo Xr |
| Genentech USA, INC. | $12,663.34 | 2019 | |
| Biogen, INC. | $10,803.89 | 2019-2021 | |
| Genzyme Corporation | $8,656.31 | 2019 | |
| Abbvie INC. | $292.19 | 2021-2025 | |
| Tg Therapeutics, INC. | $126.26 | 2025 | |
| Ucb, INC. | $102.85 | 2025 | Fintepla |
| Alnylam Pharmaceuticals INC. | $81.35 | 2024 | Onpattro |
| Amneal Pharmaceuticals LLC | $50.07 | 2025 | Crexont |
| Tepha INC | $47.46 | 2019 | |
| Eisai INC. | $43.43 | 2024 | |
| Abbott Laboratories | $34.77 | 2023 | Infinity |
| Neurocrine Biosciences, INC. | $32.84 | 2021 | |
| Microtransponder, INC. | $32.52 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $23.35 | 2024 | Apokyn |
| Pfizer INC. | $17.56 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.